PDCD1 and hepatocellular carcinoma: Using two independent C57BL/6 orthotopic HCC xenograft assays, we demonstrated that inhibiting FAP by Ac-Gly-BoroPro limited tumor growth, and this synergized with anti-PD-1 treatment (Fig. 5p‒s; Supplementary Fig. S5l‒n).